COGT
Price
$12.08
Change
-$0.29 (-2.34%)
Updated
Aug 28 closing price
Capitalization
1.69B
80 days until earnings call
ZVRA
Price
$9.30
Change
-$0.06 (-0.64%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
522.06M
68 days until earnings call
Interact to see
Advertisement

COGT vs ZVRA

Header iconCOGT vs ZVRA Comparison
Open Charts COGT vs ZVRABanner chart's image
Cogent Biosciences
Price$12.08
Change-$0.29 (-2.34%)
Volume$1.09M
Capitalization1.69B
Zevra Therapeutics
Price$9.30
Change-$0.06 (-0.64%)
Volume$35.2K
Capitalization522.06M
COGT vs ZVRA Comparison Chart in %
Loading...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COGT vs. ZVRA commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COGT is a StrongBuy and ZVRA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (COGT: $12.08 vs. ZVRA: $9.30)
Brand notoriety: COGT and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COGT: 37% vs. ZVRA: 65%
Market capitalization -- COGT: $1.69B vs. ZVRA: $522.06M
COGT [@Biotechnology] is valued at $1.69B. ZVRA’s [@Biotechnology] market capitalization is $522.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COGT’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 0 green FA rating(s).

  • COGT’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, COGT is a better buy in the long-term than ZVRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COGT’s TA Score shows that 4 TA indicator(s) are bullish while ZVRA’s TA Score has 5 bullish TA indicator(s).

  • COGT’s TA Score: 4 bullish, 5 bearish.
  • ZVRA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ZVRA is a better buy in the short-term than COGT.

Price Growth

COGT (@Biotechnology) experienced а +2.63% price change this week, while ZVRA (@Biotechnology) price change was -2.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Reported Earning Dates

COGT is expected to report earnings on Nov 17, 2025.

ZVRA is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COGT($1.69B) has a higher market cap than ZVRA($522M). COGT YTD gains are higher at: 54.872 vs. ZVRA (11.511). ZVRA has higher annual earnings (EBITDA): 36.4M vs. COGT (-299.34M). COGT has more cash in the bank: 238M vs. ZVRA (203M). COGT (60.7M) and ZVRA (62.3M) have identical debt. ZVRA has higher revenues than COGT: ZVRA (62M) vs COGT (0).
COGTZVRACOGT / ZVRA
Capitalization1.69B522M323%
EBITDA-299.34M36.4M-822%
Gain YTD54.87211.511477%
P/E RatioN/AN/A-
Revenue062M-
Total Cash238M203M117%
Total Debt60.7M62.3M97%
FUNDAMENTALS RATINGS
COGT vs ZVRA: Fundamental Ratings
COGT
ZVRA
OUTLOOK RATING
1..100
6268
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
9083
SMR RATING
1..100
10087
PRICE GROWTH RATING
1..100
3753
P/E GROWTH RATING
1..100
10024
SEASONALITY SCORE
1..100
39n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZVRA's Valuation (79) in the null industry is in the same range as COGT (87) in the Miscellaneous industry. This means that ZVRA’s stock grew similarly to COGT’s over the last 12 months.

ZVRA's Profit vs Risk Rating (83) in the null industry is in the same range as COGT (90) in the Miscellaneous industry. This means that ZVRA’s stock grew similarly to COGT’s over the last 12 months.

ZVRA's SMR Rating (87) in the null industry is in the same range as COGT (100) in the Miscellaneous industry. This means that ZVRA’s stock grew similarly to COGT’s over the last 12 months.

COGT's Price Growth Rating (37) in the Miscellaneous industry is in the same range as ZVRA (53) in the null industry. This means that COGT’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's P/E Growth Rating (24) in the null industry is significantly better than the same rating for COGT (100) in the Miscellaneous industry. This means that ZVRA’s stock grew significantly faster than COGT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COGTZVRA
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 8 days ago
81%
Declines
ODDS (%)
Bearish Trend 22 days ago
83%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PSPFX4.820.06
+1.26%
US Global Investors Global Res
NMUAX11.27N/A
N/A
Neuberger Berman Multi-Cap Opp A
ODVCX39.25N/A
N/A
Invesco Developing Markets C
HGHSX37.53N/A
N/A
Hartford Healthcare R4
JCCAX16.60N/A
N/A
JHancock Small Cap Core A

COGT and

Correlation & Price change

A.I.dvisor indicates that over the last year, COGT has been loosely correlated with SPHDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COGT jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COGT
1D Price
Change %
COGT100%
-2.34%
SPHDF - COGT
63%
Loosely correlated
N/A
IDYA - COGT
50%
Loosely correlated
-0.28%
CGON - COGT
50%
Loosely correlated
+0.89%
ATXS - COGT
50%
Loosely correlated
+0.31%
XNCR - COGT
48%
Loosely correlated
+0.37%
More